Citi analyst Graham Parry raised the firm’s price target on GSK (GSK) to 2,250 GBp from 1,900 GBp and keeps a Neutral rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GSK price target raised to 2,350 GBp from 2,100 GBp at BofA
- GSK price target raised to $70 from $55 at TD Cowen
- Balancing Blenrep Upside With Valuation and Execution Risks: Why the Risk‑Reward Remains a Hold
- Balancing Strategic Promise and Execution Risk: Justifying a Hold Rating on GSK
- GSK Earnings Call: Specialty Strength Amid Vaccine Drags